A leading clinical research organization (CRO) called LSK Global Pharma Services (PS) has inked a deal with the International Vaccine Institute’s (IVI) clinical trials of Inovio’s INO-4800, a DNA-based COVID-19 vaccine candidate in Korea. In this study, IVI, Seoul National University Hospital, and SNU Bundang Hospital will spearhead the Phase 1 and 2 clinical trials of IVO-4800 in that Asian nation. LSK will serve as CRO overseeing the overall operations: from project management to monitoring, data management, and pharmacovigilance activities.
The Goal: First Approved Vaccine in Korea?
Lee Young, President of LSK Global PS, commented for the Korean Biomedical Review that “We are honored to conduct the first approved clinical trial of a COVID-19 vaccine in Korea and play our role as a leading contract research organization (CRO) in addressing the growing expectations for a COVID-19 vaccine.”
While Jerome Kim, Director General of IVI, commented that they were pleased that they have selected LSK Global PS.
About LSK Global PS
LSK Global PS positions itself as a leading CRO in Korea. The business was founded in 2000 and has since evolved to become a one-stop, full-service CRO encompassing all of the major areas of clinical research. By the end of 2019, the company had conducted about 1,153 clinical trials, including 646 Phase 3 registration trials and about 134 global clinical trials.
Call to Action: Interested in running clinical trials in Korea, consider LSK Global PS.